TBI 304

Drug Profile

TBI 304

Alternative Names: HRC-304; TBI 304H; TBI-304

Latest Information Update: 09 May 2015

Price : $50

At a glance

  • Originator Hemosol BioPharma
  • Developer Therapure Biopharma
  • Class Antianaemics; Monoclonal antibodies
  • Mechanism of Action CD163 antigen stimulants; Erythropoiesis stimulants; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chemotherapy-induced anaemia

Most Recent Events

  • 09 Apr 2015 Phase-I clinical trials in Chemotherapy-induced anaemia in USA (Parenteral)
  • 11 Mar 2015 Therapure Biopharma receives an approval from the US FDA to proceed with phase I trial of TBI 304H in Chemotherapy-induced anaemia
  • 11 Mar 2015 Therapure Biopharma plans a phase I trial in Chemotherapy-induced anaemia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top